Abstract 4367279: Genetic Ablation of Mitochondrial H <sub>2</sub> S Producing Enzyme 3-Mercaptopyruvate Sulfurtransferase Drives Branched-Chain Amino Acids Catabolic Defect in HFrEF and HFpEF

Z Zhen Li J Jake Doiron (LSU Health Sciences Center, New Orleans, Louisiana, United States) T Timothy Allerton (Pennington Biomedical Research Cent, Baton Rouge, Louisiana, United States) H Huijing Xia T Thomas Sharp (University of South Florida, Tampa, Florida, United States) X Xiaoman Yu N Noriyuki Nagahara (Nippon Medical School, Tokyo, Japan) T Traci Goodchild (Smidt Heart Institute Cedars Sinai, Los Angeles, California, United States) D David Lefer (Cedars-Sinai Medical Center, Los Angeles, California, United States)

Abstract

Background: Impaired branched-chain amino acid (BCAA) catabolism contributes to the development and progression of heart failure (HF). However, the mechanisms regulating BCAA catabolism under physiological and pathological conditions remain incompletely understood. 3-Mercaptopyruvate sulfurtransferase (3-MST), a mitochondrial hydrogen sulfide (H 2 S)-producing enzyme, may play a critical role in this context. We investigated the role of 3-MST-derived mitochondrial H 2 S in modulating myocardial BCAA catabolism in two distinct HF models. Methods: Global 3-MST knockout (KO) and wild-type (WT) mice were investigated. Heart failure with reduced ejection fraction (HFrEF) was induced by transverse aortic constriction, while HF with preserved ejection fraction (HFpEF) was established via L-NAME administration in conjunction with a high-fat diet. Targeted metabolomic analyses were performed to assess BCAA catabolism. Cardiac function and exercise capacity were evaluated using echocardiography, invasive hemodynamics, and treadmill testing. Results: At baseline, 3-MST KO hearts exhibited reduced mitochondrial H 2 S production accompanied by modest impairment in BCAA catabolism. Under HF conditions, BCAA catabolic defects were markedly aggravated in 3-MST KO mice, as evidenced by the accumulation of BCAA metabolic intermediates in both HFrEF and HFpEF hearts compared to WT controls. These metabolic impairments were associated with worsened HF phenotypes, including reduced left ventricular ejection fraction in HFrEF, increased E/e′ ratio in HFpEF, elevated left ventricular end-diastolic pressure, and diminished exercise performance in both HF models. Additionally, skeletal muscle from 3-MST KO mice showed downregulation of BCAA catabolic enzymes. Notably, treatment with exogenous H 2 S donors restored BCAA catabolism and ameliorated cardiac dysfunction in 3-MST-deficient mice. Conclusion: These findings identify mitochondrial H 2 S produced by 3-MST as a key regulator of myocardial BCAA catabolism and HF pathophysiology. Loss of 3-MST disrupts BCAA catabolic homeostasis and exacerbates cardiac dysfunction in both HFrEF and HFpEF. Therapeutic replenishment of H 2 S may represent an effective strategy to restore metabolic balance and improve outcomes in HF. Ongoing studies aim to further elucidate the molecular interactions between 3-MST and key enzymes of the BCAA catabolic pathway.

Article Details

Journal Circulation
Volume / Issue Vol. 152, Issue Suppl_3
Published November 04, 2025
ISSN 0009-7322
Publisher Lippincott Williams & Wilkins

Journal Info

Circulation

Lippincott Williams & Wilkins

ISSN: 0009-7322 Health Sciences

Authors (9)

Z

Zhen Li

J

Jake Doiron

LSU Health Sciences Center, New Orleans, Louisiana, United States

T

Timothy Allerton

Pennington Biomedical Research Cent, Baton Rouge, Louisiana, United States

H

Huijing Xia

T

Thomas Sharp

University of South Florida, Tampa, Florida, United States

X

Xiaoman Yu

N

Noriyuki Nagahara

Nippon Medical School, Tokyo, Japan

T

Traci Goodchild

Smidt Heart Institute Cedars Sinai, Los Angeles, California, United States

D

David Lefer

Cedars-Sinai Medical Center, Los Angeles, California, United States